Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Newswire

Comprehensive Real-Time News Feed for Teva Pharmaceutical Industries.

Results 1 - 20 of 692 in Teva Pharmaceutical Industries

  1. Now Available: Optic Neuritis Global Clinical Trials Review, H1, 2015Read the original story

    12 hrs ago | PR-inside.com

    ... Overview of Meta-IQ ApS Bionure Farma, S.L. Clinical Trial Overview of Bionure Farma, S.L. Teva Pharmaceutical Industries Limited Clinical Trial Overview of Teva Pharmaceutical Industries Limited Sanofi Clinical Trial Overview of Sanofi Novartis AG ...

    Comment?

  2. Teva Is on the Prowl and Its Stock Investors Are Taking NoticeRead the original story

    13 hrs ago | The Washington Post

    Executives at Teva Pharmaceutical Industries Ltd., the world's biggest generic drugmaker, keep dropping hints that they're ready to make a large acquisition. After Chief Executive Officer Erez Vigodman said last month that Teva, which is Israel's largest publicly traded company, would shift to an "inorganic growth" strategy, analysts churned out a flurry of research notes speculating on potential acquisition targets.

    Comment?

  3. Recent Study: Generics in the NetherlandsRead the original story

    Saturday | PR-inside.com

    ... of rivalry 18 Leading Companies 19 Mylan Inc. 19 Sandoz International GmbH 22 Sanofi SA 23 Teva Pharmaceutical Industries Limited 26 Macroeconomic Indicators 29 Country Data 29 Appendix 31 Methodology 31 Industry associations 32 Related MarketLine ...

    Comment?

  4. Growth Hormone Deficiency - Pipeline Review, H1 2015 - New Market Research ReportRead the original story

    Saturday | PR-inside.com

    ... Pvt. Ltd., LG Life Sciences, Ltd., OPKO Health, Inc., Pfenex Inc., Prometheon Pharma, LLC, Teva Pharmaceutical Industries Limited, Versartis, Inc., XL-protein GmbH About Global Markets Direct Global Markets Direct is a leading provider of global ...

    Comment?

  5. Has Orexigen Delivered A Death Knell To Vivus?Read the original story w/Photo

    Friday Mar 27 | Seeking Alpha

    Orexigen's Contrave has already passed Qsymia in new scrips and is on the cusp of passing Qsymia in total scripts. Vivus investors that invested into the company because of the anti-obesity pill Qsymia have been scratching their heads for quite some time.

    Comment?

  6. Ibd TVRead the original story w/Photo

    Feb 26, 2015 | Investor's Business Daily

    ... is moving on the launch of new drugs and rumors of a buyout from fellow generic drugmaker, Teva Pharmaceutical Industries. Part of the recent wave of restaurant IPO stocks that includes Shake Shack and Habit, Zoe's is near a new buy point in a ...

    Comment?

  7. PepsiCo, Inc. (PEP), EMC Corporation (EMC): Hedge Fund Tigershark Partners to Close DoorsRead the original story w/Photo

    Thursday Mar 26 | Insider Monkey

    ... in over half of its holdings. Continuing to lead the way was the fund's investment in Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA ) , which has been its top pick for several quarters. Tigershark had a 180,000 share position in Tigershark ...

    Comment?

  8. ERYTECH Appoints New Independent Board MemberRead the original story

    Thursday Mar 26 | Business Wire

    ERYTECH Pharma , the French biopharmaceutical company that develops innovative 'tumor starvation' treatments for acute leukemia and other oncology indications with unmet medical needs, announces it has coopted Luc Dochez as new independent board member and will propose his appointment at the upcoming general assembly in June. Luc Dochez, has served as Chief Business Officer and Senior Vice-President of Business Development of Prosensa since November 2008 until its recent acquisition by Biomarin.

    Comment?

  9. Can REIT Stock Store Capital Buck Market Pressure?Read the original story w/Photo

    Feb 20, 2015 | Investor's Business Daily

    ... is moving on the launch of new drugs and rumors of a buyout from fellow generic drugmaker, Teva Pharmaceutical Industries. Part of the recent wave of restaurant IPO stocks that includes Shake Shack and Habit, Zoe's is near a new buy point in a ...

    Comment?

  10. Mylan Is One Of The Most Undervalued Generic CompaniesRead the original story w/Photo

    Thursday Mar 26 | Seeking Alpha

    Continuing my thread on U.S. pharmaceutical companies, I would like to introduce Mylan N.V., a multi-billion dollar generics manufacturer. The major difference between Mylan and the companies I covered before is that its business largely relies on production and distribution of generic drugs.

    Comment?

  11. Ex-Teva CEO Finds New Home at Neuro Startup As It Raises $5MRead the original story

    Wednesday Mar 25 | BioSpace

    March 26, 2015 By Riley McDermid , BioSpace.com Breaking News Sr. Editor Stealth New York-based startup Ovid Therapeutics is having a big week, after news began circulate that former Teva Pharmaceutical Industries Ltd. head Jeremy Levin is chairing the company, which said in a recent filing with the U.S. Securities and Exchange Commission that it has raised $5 million. It's become clear in follow up interviews, however, that Ovid is increasingly uncomfortable with the amount of interest its attracting.

    Comment?

  12. We will regain confidence of the Us Fda: Dilip ShanghviRead the original story w/Photo

    Thursday Mar 26 | Rediff.com

    Excerpts: The focus for value creation will be on all business segments, including speciality, generics and active pharmaceutical ingredients. Also the consumer health business that is coming with Ranbaxy has huge opportunity.

    Comment?

  13. Ignyta Inc (RXDX), Horizon Pharma PLC (HZNP), Flamel Technologies...Read the original story w/Photo

    Wednesday Mar 25 | Insider Monkey

    ... financial results for the last year and announcing the acquisition of four R&D assets from Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA ). The company has received from the FDA orphan drug designation for its entrectinib, a drug for the ...

    Comment?

  14. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Tuesday Mar 24 | Business Wire

    ... notes: --$359,200,000 class A-1 'F1+sf'; --$215,000,000 class A-2A 'AAAsf'; Outlook... )--Teva Pharmaceutical Industries Limited (NYSE:TEVA) ("Teva") announced today that it priced a a 2 billion debt offering, comprised of two tranches: a 1.3 ...

    Comment?

  15. Teva Announces Pricing of a 2 Billion of Senior NotesRead the original story

    Tuesday Mar 24 | Business Wire

    )--Teva Pharmaceutical Industries Limited (NYSE:TEVA) ("Teva") announced today that it priced a a 2 billion debt offering, comprised of two tranches: a 1.3 billion principal amount of 1.250% senior notes due March 2023 and a 700 million principal ...

    Comment?

  16. Fitch Rates Teva's Euro Bond Offering 'BBB+'Read the original story

    Tuesday Mar 24 | Reuters

    ... olid free cash flow (FCF) of $3 billion to $3.5 billion in 2015. Fitch rates Teva as follows: Teva Pharmaceutical Industries Limited --IDR at 'BBB+', Outlook Stable. Teva Pharmaceuticals USA, Inc. -

    Comment?

  17. Teva Announces New Head of Business Development, Strategy and InnovationRead the original story w/Photo

    Monday Mar 23 | Pharmaceutical Processing

    Teva Pharmaceutical Industries has announced the appointment of Timothy R. Wright to the Company's executive leadership team, heading business development, strategy and innovation. In this new role, Mr. Wright will be responsible for identifying new sources of innovation and growth that are extensions of Teva's business model.

    Comment?

  18. Teva's TEV-48125 Meets Primary And Secondary Endpoints In Episodic...Read the original story

    Sunday Mar 22 | BioSpace

    Teva Pharmaceutical Industries Ltd. announced today the successful completion of its Phase IIb migraine prevention program with positive top-line results from a Phase IIb study evaluating the efficacy, safety and tolerability of two doses of subcutaneous TEV-48125 for the prevention of high frequency episodic migraine . "Our phase II results are striking in their clarity.

    Comment?

  19. Teva Migraine Drug Scores In Race With Alder, LillyRead the original story w/Photo

    Monday Mar 23 | Investor's Business Daily

    The trial met its endpoint of a statistically significant reduction in days of migraine and headache compared to the placebo group. Teva's press release added that "these results were achieved in the presence of patients being allowed to remain on existing migraine prevention therapy, and without limitation on the amount of acute migraine treatment used.

    Comment?

  20. Ohio State tech commercialization chief leavingRead the original story w/Photo

    Monday Mar 23 | Business Journal

    The interim leader of Ohio State University's Technology Commercialization Office is taking a new job, leaving a deeper gap in the school's efforts to license out products from its research. Tim Wright will depart the OSU gig in three weeks to lead the innovation hunt for Teva Pharmaceutical Industries Ltd. , the world's largest generic drug-maker.

    Comment?